Submit Full Adverse Event Data from Lenvatinib Phase IV Liver Cancer Trial: CDSCO Panel To Eisai Pharma

During the meeting, the committee noted that adverse events were reported during the course of the study. However, the firm did not present the complete details of these adverse events or provide any corresponding assessment reports explaining causality, severity, or resolution.

After detailed deliberation, the SEC recommended that Eisai Pharmaceuticals must submit the complete adverse event data and corresponding assessment reports related to the Phase IV study to CDSCO. These submissions will be required for further regulatory review and to determine the safety profile of the drug in the post-marketing setting.

"Submit the complete details of adverse events reported during the Phase IV CT study along with its assessment reports to CDSCO for further review by the committee," the expert panel noted.

Lenvatinib, an oral multikinase inhibitor, is approved for the treatment of unresectable hepatocellular carcinoma (HCC), one of the most common forms of liver cancer. It works by blocking multiple receptors involved in tumor angiogenesis and proliferation, including VEGFR, FGFR, and PDGFR.

Eisai Pharmaceuticals India Pvt. Ltd, a subsidiary of Eisai Co., Ltd., Japan, has a global presence in oncology, neurology, and rare diseases. The company markets Lenvatinib in India and other regions under its oncology portfolio and is conducting Phase IV trials as part of post-marketing surveillance obligations.